Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, September 2002, p. 3075-3079, Vol. 46, No. 9
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.9.3075-3079.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Prevalence of Protease and Reverse Transcriptase Drug Resistance Mutations over Time in Drug-Naïve Human Immunodeficiency Virus Type 1-Positive Individuals in Rio de Janeiro, Brazil
Ana T. Dumans,1 Marcelo A. Soares,2 Danuta Pieniazek,3 Marcia L. Kalish,3 Veronique De Vroey,4 Kurt Hertogs,4 and Amilcar Tanuri2*
Unidade de Genetica, Departamento de Ciencias Morfologicas, Instituto Biomedico, Universidade do Rio de Janeiro,1
Laboratório de Virologia Molecular, Departamento de Genética, Universidade Federal do Rio de Janeiro, Cidade UniversitáriaIlha do Fundão, Rio de Janeiro, Rio de Janeiro, Brazil,2
HIV and Retrovirology Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333 ,3
Tibotec-VIRCO NV, B-2800 Mechelen, Belgium4
Received 25 January 2002/
Returned for modification 23 April 2002/
Accepted 13 May 2002
The prevalence of mutations that confer resistance to protease inhibitors and to nucleoside and nonnucleoside reverse transcriptase inhibitors in 49 blood samples from drug-naïve human immunodeficiency virus type 1-infected blood donors living in Rio de Janeiro state, Brazil, in 1998 was evaluated genotypically and phenotypically.
* Corresponding author. Mailing address: Laboratório de Virologia Molecular, Departamento de Genética, Universidade Federal do Rio de Janeiro, CCSBl. A, sala A2-121, Cidade UniversitáriaIlha do Fundão, Rio de Janeiro RJ 21944-970, Brazil. Phone: 55-21-2562-6385. Fax: 55-21-2562-6397. E-mail:
atanuri{at}biologia.ufrj.br.
Antimicrobial Agents and Chemotherapy, September 2002, p. 3075-3079, Vol. 46, No. 9
0066-4804/02/$04.00+0 DOI: 10.1128/AAC.46.9.3075-3079.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
This article has been cited by other articles:
-
Taiwo, B. O., Murphy, R.
(2007). Transmitted Resistance: An Overview and Its Potential Relevance to the Management of HIV-Infected Persons in Resource-Limited Settings. J Int Assoc Physicians AIDS Care (Chic Ill)
6: 188-197
[Abstract]
-
Hazen, R., Harvey, R., Ferris, R., Craig, C., Yates, P., Griffin, P., Miller, J., Kaldor, I., Ray, J., Samano, V., Furfine, E., Spaltenstein, A., Hale, M., Tung, R., St. Clair, M., Hanlon, M., Boone, L.
(2007). In Vitro Antiviral Activity of the Novel, Tyrosyl-Based Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor Brecanavir (GW640385) in Combination with Other Antiretrovirals and against a Panel of Protease Inhibitor-Resistant HIV. Antimicrob. Agents Chemother.
51: 3147-3154
[Abstract]
[Full Text]
-
Pires, I. L., Soares, M. A., Speranza, F. A. B., Ishii, S. K., Vieira, M. C. G., Gouvea, M. I. F. S., Guimaraes, M. A. A. M., de Oliveira, F. E., Magnanini, M. M. F., Brindeiro, R. M., Tanuri, A.
(2004). Prevalence of Human Immunodeficiency Virus Drug Resistance Mutations and Subtypes in Drug-Naive, Infected Individuals in the Army Health Service of Rio de Janeiro, Brazil. J. Clin. Microbiol.
42: 426-430
[Abstract]
[Full Text]